Company & Sponsor Intelligence

Yale University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →
Indexed trials9
Recruiting3
Completed6
Countries2

Therapeutic footprint

adhdalzheimersanxietyautismunclassified

Indexed studies

NCT04242355Transcranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder
autism · United StatesNA
NCT06462430PTEN Hamartoma Tumor Syndrome Pediatric Patient Registry
autism · Turkey (Türkiye)RECRUITING
NCT06413316ABC-CT Pre-School Feasibility Study
autism · United StatesCOMPLETED
NCT02579928Ketamine Infusion for Adolescent Depression and Anxiety
anxiety · United StatesPHASE4
NCT04737512Mindfulness-Based ADHD Treatment for Children: a Feasibility Study
adhd · United StatesEARLY_PHASE1
NCT00486551Anger Control Training for Youth With Tourette Syndrome
unclassified · United StatesNA
NCT06329453Intestinal Immunity in Neurologic Disease
unclassified · United StatesRECRUITING
NCT02167256A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
alzheimers · United StatesPHASE2
NCT01567969Family Health and Development Project
unclassified · United StatesPHASE3
NCT05957159Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
unclassified · United StatesEARLY_PHASE1

Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →